Effect of Digital Cognitive Behavioral Therapy for Insomnia on Health, Psychological Well-being, and Sleep-Related Quality of Life: A Randomized Clinical Trial.


Journal

JAMA psychiatry
ISSN: 2168-6238
Titre abrégé: JAMA Psychiatry
Pays: United States
ID NLM: 101589550

Informations de publication

Date de publication:
01 01 2019
Historique:
pubmed: 29 9 2018
medline: 18 2 2020
entrez: 29 9 2018
Statut: ppublish

Résumé

Digital cognitive behavioral therapy (dCBT) is a scalable and effective intervention for treating insomnia. Most people with insomnia, however, seek help because of the daytime consequences of poor sleep, which adversely affects quality of life. To investigate the effect of dCBT for insomnia on functional health, psychological well-being, and sleep-related quality of life and to determine whether a reduction in insomnia symptoms was a mediating factor. This online, 2-arm, parallel-group randomized trial comparing dCBT for insomnia with sleep hygiene education (SHE) evaluated 1711 participants with self-reported symptoms of insomnia. Participants were recruited between December 1, 2015, and December 1, 2016, and dCBT was delivered using web and/or mobile channels plus treatment as usual; SHE comprised a website and a downloadable booklet plus treatment as usual. Online assessments took place at 0 (baseline), 4 (midtreatment), 8 (posttreatment), and 24 (follow-up) weeks. Programs were completed within 12 weeks after inclusion. Primary outcomes were scores on self-reported measures of functional health (Patient-Reported Outcomes Measurement Information System: Global Health Scale; range, 10-50; higher scores indicate better health); psychological well-being (Warwick-Edinburgh Mental Well-being Scale; range, 14-70; higher scores indicate greater well-being); and sleep-related quality of life (Glasgow Sleep Impact Index; range, 1-100; higher scores indicate greater impairment). Secondary outcomes comprised mood, fatigue, sleepiness, cognitive failures, work productivity, and relationship satisfaction. Insomnia was assessed with the Sleep Condition Indicator (range: 0-32; higher scores indicate better sleep). Of the 1711 participants included in the intention-to-treat analysis, 1329 (77.7%) were female, mean (SD) age was 48.0 (13.8) years, and 1558 (91.1%) were white. Use of dCBT was associated with a small improvement in functional health compared with SHE (adjusted difference [95% CI] at week 4, 0.90 [0.40-1.40]; week 8, 1.76 [1.24-2.28]; week 24, 1.76 [1.22-2.30]) and psychological well-being (adjusted difference [95% CI] at week 4, 1.04 [0.28-1.80]; week 8, 2.68 [1.89-3.47]; week 24, 2.95 [2.13-3.76]), and with a large improvement in sleep-related quality of life (at week 4, -8.76 [-11.83 to -5.69]; week 8, -17.60 [-20.81 to -14.39]; week 24, -18.72 [-22.04 to -15.41]) (all P < .01). A large improvement in insomnia mediated these outcomes (range mediated, 45.5%-84.0%). Use of dCBT is effective in improving functional health, psychological well-being, and sleep-related quality of life in people reporting insomnia symptoms. A reduction in insomnia symptoms mediates these improvements. These results confirm that dCBT improves both daytime and nighttime aspects of insomnia, strengthening existing recommendations of CBT as the treatment of choice for insomnia. isrctn.org identifier: ISRCTN60530898.

Identifiants

pubmed: 30264137
pii: 2704019
doi: 10.1001/jamapsychiatry.2018.2745
pmc: PMC6583463
doi:

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

21-30

Subventions

Organisme : Department of Health
ID : RP-2014-05-003
Pays : United Kingdom

Références

Health Technol Assess. 2015 Nov;19(93):1-115, v-vi
pubmed: 26560448
Diabetes Care. 2010 Feb;33(2):414-20
pubmed: 19910503
Curr Psychiatry Rep. 2017 Aug;19(8):44
pubmed: 28616860
Sleep Med Rev. 2010 Feb;14(1):69-82
pubmed: 19962922
Lancet Psychiatry. 2017 Oct;4(10):749-758
pubmed: 28888927
Behav Sleep Med. 2006;4(2):71-84
pubmed: 16579717
Diabetes Care. 2009 Nov;32(11):1980-5
pubmed: 19641160
Sleep. 2007 Mar;30(3):274-80
pubmed: 17425223
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941
Arch Gen Psychiatry. 2004 Mar;61(3):310-7
pubmed: 14993119
Arch Intern Med. 2006 May 22;166(10):1092-7
pubmed: 16717171
J Clin Psychiatry. 2012 Dec;73(12):e1478-84
pubmed: 23290331
J Clin Sleep Med. 2007 Dec 15;3(7):722-8
pubmed: 18198807
J Am Geriatr Soc. 2016 Sep;64(9):1830-8
pubmed: 27550552
Behav Res Ther. 2016 Dec;87:109-116
pubmed: 27658218
Qual Life Res. 2009 Sep;18(7):873-80
pubmed: 19543809
J Clin Sleep Med. 2017 Mar 15;13(3):401-410
pubmed: 27923435
Trials. 2016 May 23;17(1):257
pubmed: 27216112
BMC Fam Pract. 2012 May 25;13:40
pubmed: 22631616
Sleep Med Rev. 2016 Dec;30:1-10
pubmed: 26615572
Sleep Med Rev. 2002 Apr;6(2):97-111
pubmed: 12531146
Sleep Med Rev. 2009 Jun;13(3):205-14
pubmed: 19201632
Sleep Med. 2011 Sep;12(8):735-47
pubmed: 21907616
Qual Life Res. 2014 Dec;23(10):2809-18
pubmed: 24890827
Br J Clin Psychol. 1982 Feb;21(1):1-16
pubmed: 7126941
Am J Hypertens. 2017 Mar 1;30(3):319-327
pubmed: 28391289
J Clin Oncol. 2008 Oct 1;26(28):4651-8
pubmed: 18591549
J Sleep Med Disord. 2015;2(2):
pubmed: 32195356
Am J Health Promot. 2005 Jan-Feb;19(3):194-8
pubmed: 15693347
J Clin Psychol Med Settings. 2011 Sep;18(3):312-21
pubmed: 21629999
Sleep. 1999 May 1;22 Suppl 2:S354-8
pubmed: 10394607
Behav Res Ther. 2008 May;46(5):623-41
pubmed: 18417099
J Pers Soc Psychol. 1986 Dec;51(6):1173-82
pubmed: 3806354
Curr Sleep Med Rep. 2017;3(2):48-56
pubmed: 28553574
Ann Intern Med. 2016 Jul 19;165(2):125-33
pubmed: 27136449
J Occup Environ Med. 2016 Jul;58(7):683-9
pubmed: 27257747
Lancet Psychiatry. 2016 Apr;3(4):333-41
pubmed: 26827250
J Cancer Surviv. 2017 Jun;11(3):401-409
pubmed: 28105576
Sleep Med. 2014 Aug;15(8):913-7
pubmed: 24791643
Pharmacoeconomics. 1993 Nov;4(5):353-65
pubmed: 10146874
BMJ Open. 2014 Mar 18;4(3):e004183
pubmed: 24643168
J Appl Psychol. 2017 Jan;102(1):104-113
pubmed: 27690480
J Sleep Res. 2017 Dec;26(6):675-700
pubmed: 28875581
BMJ. 2006 Jun 24;332(7556):1506-8
pubmed: 16793819
Psychol Med. 2019 Feb;49(3):491-500
pubmed: 29792241
Sleep Med Clin. 2017 Jun;12(2):167-177
pubmed: 28477772
Sleep. 2012 Jun 01;35(6):769-81
pubmed: 22654196
NIH Consens State Sci Statements. 2005 Jun 13-15;22(2):1-30
pubmed: 17308547
Sleep. 2008 Apr;31(4):489-95
pubmed: 18457236
Health Qual Life Outcomes. 2007 Nov 27;5:63
pubmed: 18042300
Sleep. 2007 May;30(5):574-84
pubmed: 17552372
Behav Res Ther. 2001 Jan;39(1):45-60
pubmed: 11125723
Curr Sleep Med Rep. 2015 Sep;1(3):157-165
pubmed: 26500835
Sleep. 1991 Dec;14(6):540-5
pubmed: 1798888
Sleep Med. 2006 Mar;7(2):123-30
pubmed: 16459140
Sleep Med. 2013 Jun;14(6):493-501
pubmed: 23347908
J Psychopharmacol. 2010 Nov;24(11):1577-601
pubmed: 20813762
Sleep Med Rev. 2018 Apr;38:3-16
pubmed: 28392168
PLoS One. 2016 Feb 11;11(2):e0149139
pubmed: 26867139

Auteurs

Colin A Espie (CA)

Sleep & Circadian Neuroscience Institute, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom.
Big Health Ltd, London, United Kingdom.

Richard Emsley (R)

Biostatistics & Health Informatics Department, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom.

Simon D Kyle (SD)

Sleep & Circadian Neuroscience Institute, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom.

Christopher Gordon (C)

Susan Wakil School of Nursing and Midwifery, The University of Sydney, Sydney, Australia.
CIRUS Centre for Integrated Research and Understanding of Sleep, Woolcock Institute of Medical Research, University of Sydney, Sydney, Australia.

Christopher L Drake (CL)

Department of Sleep Disorders and Research Center, Henry Ford Health System, Detroit, Michigan.

A Niroshan Siriwardena (AN)

School of Health and Social Care, University of Lincoln, Lincoln, United Kingdom.

John Cape (J)

Big Health Ltd, London, United Kingdom.
Division of Psychology and Language Sciences, Faculty of Brain Sciences, University College London, London, United Kingdom.

Jason C Ong (JC)

Feinberg School of Medicine, Northwestern University, Chicago, Illinois.

Bryony Sheaves (B)

Sleep & Circadian Neuroscience Institute, Department of Psychiatry, University of Oxford, Oxford, United Kingdom.

Russell Foster (R)

Sleep & Circadian Neuroscience Institute, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom.

Daniel Freeman (D)

Sleep & Circadian Neuroscience Institute, Department of Psychiatry, University of Oxford, Oxford, United Kingdom.

Joan Costa-Font (J)

Department of Health Policy, The London School of Economics and Political Science, London, United Kingdom.

Antonia Marsden (A)

Centre for Biostatistics, School of Health Sciences, The University of Manchester, Manchester, United Kingdom.

Annemarie I Luik (AI)

Sleep & Circadian Neuroscience Institute, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom.
Big Health Ltd, London, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH